Arno Therapeutics, Inc. (ARNI)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 | - USD | 0.0% |
| 2021 | - USD | 0.0% |
| 2020 | - USD | 0.0% |
| 2019 | - USD | 0.0% |
| 2015 | 8.98 Million USD | 1.68% |
| 2014 | 8.83 Million USD | -77.78% |
| 2013 | 39.76 Million USD | 58.07% |
| 2012 | 25.15 Million USD | 343.79% |
| 2011 | 5.66 Million USD | 4.7% |
| 2010 | 5.41 Million USD | 217.04% |
| 2009 | 1.7 Million USD | -42.45% |
| 2008 | 2.96 Million USD | 17220.69% |
| 2007 | 17.13 Thousand USD | -67.28% |
| 2006 | 52.36 Thousand USD | 38.15% |
| 2005 | 37.9 Thousand USD | -26.91% |
| 2004 | 51.85 Thousand USD | 13.08% |
| 2003 | 45.85 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 FY | - USD | 0.0% |
| 2021 FY | - USD | 0.0% |
| 2020 FY | - USD | 0.0% |
| 2019 FY | - USD | 0.0% |
| 2016 Q1 | 6.94 Million USD | -22.68% |
| 2016 Q2 | 6.31 Million USD | -9.07% |
| 2016 Q3 | 8.06 Million USD | 27.74% |
| 2015 Q2 | 8.07 Million USD | -0.99% |
| 2015 Q1 | 8.15 Million USD | -7.71% |
| 2015 Q3 | 5.65 Million USD | -29.98% |
| 2015 Q4 | 8.98 Million USD | 58.91% |
| 2015 FY | 8.98 Million USD | 1.68% |
| 2014 FY | 8.83 Million USD | -77.78% |
| 2014 Q1 | 33.67 Million USD | -15.32% |
| 2014 Q4 | 8.83 Million USD | -50.8% |
| 2014 Q2 | 23.36 Million USD | -30.61% |
| 2014 Q3 | 17.96 Million USD | -23.13% |
| 2013 Q1 | 21.95 Million USD | -12.75% |
| 2013 FY | 39.76 Million USD | 58.07% |
| 2013 Q4 | 39.76 Million USD | 35.93% |
| 2013 Q3 | 29.25 Million USD | 0.72% |
| 2013 Q2 | 29.04 Million USD | 32.33% |
| 2012 Q1 | 5.7 Million USD | 0.71% |
| 2012 Q3 | 4.89 Million USD | 47.3% |
| 2012 Q2 | 3.32 Million USD | -41.79% |
| 2012 FY | 25.15 Million USD | 343.79% |
| 2012 Q4 | 25.15 Million USD | 413.94% |
| 2011 Q1 | 5.68 Million USD | 5.01% |
| 2011 Q4 | 5.66 Million USD | 0.29% |
| 2011 FY | 5.66 Million USD | 4.7% |
| 2011 Q3 | 5.65 Million USD | -5.22% |
| 2011 Q2 | 5.96 Million USD | 4.89% |
| 2010 FY | 5.41 Million USD | 217.04% |
| 2010 Q4 | 5.41 Million USD | 0.0% |
| 2009 FY | 1.7 Million USD | -42.45% |
| 2008 FY | 2.96 Million USD | 17220.69% |
| 2008 Q1 | 34.36 Thousand USD | 100.57% |
| 2008 Q3 | 2.87 Million USD | 48.13% |
| 2008 Q4 | 2.96 Million USD | 3.23% |
| 2008 Q2 | 1.94 Million USD | 5547.7% |
| 2007 Q2 | 62.56 Thousand USD | 11.8% |
| 2007 Q3 | - USD | -100.0% |
| 2007 Q4 | 17.13 Thousand USD | 0.0% |
| 2007 FY | 17.13 Thousand USD | -67.28% |
| 2007 Q1 | 55.96 Thousand USD | 6.87% |
| 2006 FY | 52.36 Thousand USD | 38.15% |
| 2006 Q4 | 52.36 Thousand USD | 8.27% |
| 2006 Q3 | 48.36 Thousand USD | 4.31% |
| 2006 Q2 | 46.36 Thousand USD | 13.45% |
| 2006 Q1 | 40.86 Thousand USD | 7.82% |
| 2005 Q4 | 37.9 Thousand USD | 3.54% |
| 2005 Q1 | 53.35 Thousand USD | 2.89% |
| 2005 Q3 | 36.6 Thousand USD | 0.0% |
| 2005 FY | 37.9 Thousand USD | -26.91% |
| 2004 Q3 | 52.11 Thousand USD | 3.61% |
| 2004 Q2 | 50.29 Thousand USD | 3.78% |
| 2004 FY | 51.85 Thousand USD | 13.08% |
| 2004 Q4 | 51.85 Thousand USD | -0.49% |
| 2004 Q1 | 48.46 Thousand USD | 0.0% |
| 2003 FY | 45.85 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | 100.0% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 100.0% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 100.0% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | 100.0% |
| Rebus Holdings, Inc. | 5.24 Million USD | 100.0% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 100.0% |
| Qrons Inc. | 1.48 Million USD | 100.0% |
| Adynxx, Inc. | - USD | NaN% |
| Neon Bloom, Inc. | 1.22 Million USD | 100.0% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 100.0% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | 100.0% |
| Skye Bioscience, Inc. | 14.07 Million USD | 100.0% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 100.0% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 100.0% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | 100.0% |
| SQZ Biotechnologies Company | 50.03 Million USD | 100.0% |
| Intellipharmaceutics International Inc. | 12 Million USD | 100.0% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 100.0% |
| Mesoblast Limited | 188.44 Million USD | 100.0% |
| Marizyme, Inc. | 26.67 Million USD | 100.0% |
| Genus plc | 485 Million USD | 100.0% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 100.0% |
| Pharming Group N.V. | 244.07 Million USD | 100.0% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | 100.0% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 100.0% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 100.0% |
| ContraFect Corporation | 32.53 Million USD | 100.0% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | 100.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | NaN% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 100.0% |
| IMV Inc. | 37.93 Million USD | 100.0% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 100.0% |
| MultiCell Technologies, Inc. | 1617.67 USD | 100.0% |
| ONE Bio Corp. | 27.49 Million USD | 100.0% |
| Accustem Sciences Inc. | 1.07 Million USD | 100.0% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 100.0% |
| EV Biologics, Inc. | 2.11 Million USD | 100.0% |
| Q BioMed Inc. | 8.13 Million USD | 100.0% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 100.0% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 100.0% |
| Biomind Labs Inc. | 1.49 Million USD | 100.0% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 100.0% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 100.0% |
| TetraLogic Pharmaceuticals Corporation | - USD | NaN% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 100.0% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | 100.0% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | 100.0% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | 100.0% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 100.0% |
| GB Sciences, Inc. | 5.41 Million USD | 100.0% |
| Alpha Cognition Inc. | 7.16 Million USD | 100.0% |
| HST Global, Inc. | 593.59 Thousand USD | 100.0% |
| CSL Limited | 18.62 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | 1.25 Million USD | 100.0% |
| Halberd Corporation | 728.71 Thousand USD | 100.0% |
| Enzolytics Inc. | 365.26 Million USD | 100.0% |
| Agentix Corp. | 2.51 Million USD | 100.0% |
| Resverlogix Corp. | 67.39 Million USD | 100.0% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | 100.0% |
| MetaStat, Inc. | - USD | NaN% |
| argenx SE | 444.95 Million USD | 100.0% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | 100.0% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 100.0% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 100.0% |
| GeneThera, Inc. | - USD | NaN% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 100.0% |
| AVAX Technologies, Inc. | 3.99 Million USD | 100.0% |
| Zenith Capital Corp. | 27.56 Thousand USD | 100.0% |
| Genscript Biotech Corporation | 1.32 Billion USD | 100.0% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | 100.0% |
| Anthera Pharmaceuticals, Inc. | - USD | NaN% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 100.0% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | 100.0% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 100.0% |
| Kadimastem Ltd | 3.5 Million USD | 100.0% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | 100.0% |
| VitaSpring Biomedical Co. Ltd. | - USD | NaN% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 100.0% |
| BioStem Technologies, Inc. | 15.9 Million USD | 100.0% |
| Oncology Pharma Inc. | - USD | NaN% |
| Reve Technologies, Inc. | 464.69 Thousand USD | 100.0% |
| LadRx Corporation | 2.2 Million USD | 100.0% |
| Cell Source, Inc. | 15.8 Million USD | 100.0% |
| Regen BioPharma, Inc. | 5.45 Million USD | 100.0% |
| Regen BioPharma, Inc. | 5.45 Million USD | 100.0% |
| NovAccess Global Inc. | 7.86 Million USD | 100.0% |
| Affymax, Inc. | 8.87 Million USD | 100.0% |
| Itoco Inc. | 1.65 Million USD | 100.0% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | 100.0% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 100.0% |
| Mobile Lads Corp. | 1.31 Million USD | 100.0% |
| CytoDyn Inc. | 127.89 Million USD | 100.0% |
| Claritas Pharmaceuticals, Inc. | - USD | NaN% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | 100.0% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | 100.0% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 100.0% |
| SYBLEU INC | 681.41 Thousand USD | 100.0% |
| Advanced Proteome Therapeutics Corporation | - USD | NaN% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 100.0% |
| International Stem Cell Corporation | 5.27 Million USD | 100.0% |
| Bioxytran, Inc. | 3.24 Million USD | 100.0% |
| GlobeImmune, Inc. | - USD | NaN% |
| Predictive Technology Group, Inc. | - USD | NaN% |
| ProText Mobility, Inc. | 625.8 Thousand USD | 100.0% |
| Cardax, Inc. | - USD | NaN% |
| VG Life Sciences Inc. | 4.61 Million USD | 100.0% |
| Kaleido Biosciences, Inc. | - USD | NaN% |
| Advaxis, Inc. | 40.99 Million USD | 100.0% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 100.0% |
| RenovaCare, Inc. | - USD | NaN% |
| Regnum Corp. | 2.02 Million USD | 100.0% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 100.0% |
| Neutra Corp. | 973.52 Thousand USD | 100.0% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 100.0% |
| PureTech Health plc | 125.58 Million USD | 100.0% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 100.0% |
| IXICO plc | 1.9 Million USD | 100.0% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 100.0% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 100.0% |
| CSL Limited | 18.62 Billion USD | 100.0% |
| Cellectis S.A. | 249.36 Million USD | 100.0% |